|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel R, Ma J, Zou Z and Jemal A: Cancer
statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Potrykowska A, Strzelecki Z, Szymborski J
and Witkowski J: Cancer incidence and mortality versus the
demographic situation of PolandRządowa Rada Ludnościowa. Warsaw:
pp. 117–130. 2014, (In Polish).
|
|
4
|
Paik ES, Lee YY, Lee EJ, Choi CH, Kim TJ,
Lee JW, Bae DS and Kim BG: Survival analysis of revised 2013 FIGO
staging classification of epithelial ovarian cancer and comparison
with previous FIGO staging classification. Obstet Gynecol Sci.
58:124–134. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Suh DH, Kim TH, Kim JW, Kim SY, Kim HS,
Lee TS, Chung HH, Kim YB, Park NH and Song YS: Improvements to the
FIGO staging for ovarian cancer: Reconsideration of lymphatic
spread and intraoperative tumor rupture. J Gynecol Oncol.
24:352–358. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
van der Burg ME, van Lent M, Buyse M,
Kobierska A, Colombo N, Favalli G, Lacave AJ, Nardi M, Renard J and
Pecorelli S: The effect of debulking surgery after induction
chemotherapy on the prognosis in advanced epithelial ovarian
cancer. Gynecological cancer cooperative group of the European
Organization for research and treatment of cancer. N Engl J Med.
332:629–634. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Raja FA, Chopra N and Ledermann JA:
Optimal first-line treatment in ovarian cancer. Ann Oncol.
23:(Suppl 10). x118–x127. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lloyd KL, Cree IA and Savage RS:
Prediction of resistance to chemotherapy in ovarian cancer: A
systematic review. BMC Cancer. 15:1172015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Pliarchopoulou K and Pectasides D:
Epithelial ovarian cancer: Focus on targeted therapy. Crit Rev
Oncol Hematol. 79:17–23. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhu LC, Gao J, Hu ZH, Schwab CL, Zhuang
HY, Tan MZ, Yan LM, Liu JJ, Zhang DY and Lin B: Membranous
expressions of Lewis y and CAM-DR-related markers are independent
factors of chemotherapy resistance and poor prognosis in epithelial
ovarian cancer. Am J Cancer Res. 5:830–843. 2015.PubMed/NCBI
|
|
11
|
Vinogradov S and Wei X: Cancer stem cells
and drug resistance: The potential of nanomedicine. Nanomedicine
(Lond). 7:597–615. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Markman M and Bookman MA: Second-line
treatment of ovarian cancer. Oncologist. 5:26–35. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Cooley M, Fang P, Fang F, Nephew KP and
Chien J: Molecular determinants of chemotherapy resistance in
ovarian cancer. Pharmacogenomics. 16:1763–1767. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Foster JM, Oumie A, Togneri FS, Vasques
FR, Hau D, Taylor M, Tinkler-Hundal E, Southward K, Medlow P,
McGreeghan-Crosby K, et al: Cross-laboratory validation of the
OncoScan® FFPE Assay, a multiplex tool for whole genome
tumour profiling. BMC Med Genomics. 8:52015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Bast RC Jr, Hennessy B and Mills GB: The
biology of ovarian cancer: New opportunities for translation. Nat
Rev Cancer. 9:415–428. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
16
|
Musrap N, Tuccitto A, Karagiannis GS,
Saraon P, Batruch I and Diamandis EP: Comparative proteomics of
ovarian cancer aggregate formation reveals an increased expression
of calcium-activated chloride channel regulator 1 (CLCA1). J Biol
Chem. 290:17218–17227. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Burleson KM, Casey RC, Skubitz KM,
Pambuccian SE, Oegema TR Jr and Skubitz AP: Ovarian carcinoma
ascites spheroids adhere to extracellular matrix components and
mesothelial cell monolayers. Gynecol Oncol. 93:170–181. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Høgdall E: Cancer antigen 125 and
prognosis. Curr Opin Obstet Gynecol. 20:4–8. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Gadducci A, Cosio S, Fanucchi A, Negri S,
Cristofani R and Genazzani AR: The predictive and prognostic value
of serum CA 125 half-life during paclitaxel/platinum-based
chemotherapy in patients with advanced ovarian carcinoma. Gynecol
Oncol. 93:131–136. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Menon U, Skates SJ, Lewis S, Rosenthal AN,
Rufford B, Sibley K, Macdonald N, Dawnay A, Jeyarajah A, Bast RC
Jr, et al: Prospective study using the risk of ovarian cancer
algorithm to screen for ovarian cancer. J Clin Oncol. 23:7919–7926.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hasanbegovic L, Alicelebic S and Sljivo N:
Comparison of specific ovarian tumor markers by elecsys analyzer
2010. Acta Inform Med. 23:86–89. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hellström I, Raycraft J, Hayden-Ledbetter
M, Ledbetter JA, Schummer M, McIntosh M, Drescher C, Urban N and
Hellström KE: The HE4 (WFDC2) protein is a biomarker for ovarian
carcinoma. Cancer Res. 63:3695–3700. 2003.PubMed/NCBI
|
|
23
|
Moore RG, MacLaughlan S and Bast RC Jr:
Current state of biomarker development for clinical application in
epithelial ovarian cancer. Gynecol Oncol. 116:240–245. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Huhtinen K, Suvitie P, Hiissa J, Junnila
J, Huvila J, Kujari H, Setälä M, Härkki P, Jalkanen J, Fraser J, et
al: Serum HE4 concentration differentiates malignant ovarian
tumours from ovarian endometriotic cysts. Br J Cancer.
100:1315–1319. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Moore RG, Miller MC, Steinhoff MM, Skates
SJ, Lu KH, Lambert-Messerlian G and Bast RC Jr: Serum HE4 levels
are less frequently elevated than CA125 in women with benign
gynecologic disorders. Am J Obstet Gynecol. 206(351): e1–8.
2012.
|
|
26
|
Górski B, Byrski T, Huzarski T, Jakubowska
A, Menkiszak J, Gronwald J, Pluzańska A, Bebenek M,
Fischer-Maliszewska L, Grzybowska E, et al: Founder mutations in
the BRCA1 gene in Polish families with breast-ovarian cancer. Am J
Hum Genet. 66:1963–1968. 2000. View
Article : Google Scholar : PubMed/NCBI
|
|
27
|
Herman JG, Umar A, Polyak K, Graff JR,
Ahuja N, Issa JP, Markowitz S, Willson JK, Hamilton SR, Kinzler KW,
et al: Incidence and functional consequences of hMLH1 promoter
hypermethylation in colorectal carcinoma. Proc Natl Acad Sci USA.
95:6870–6875. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Curia MC, Palmirotta R, Aceto G, Messerini
L, Verì MC, Crognale S, Valanzano R, Ficari F, Fracasso P,
Stigliano V, et al: Unbalanced germ-line expression of hMLH1 and
hMSH2 alleles in hereditary nonpolyposis colorectal cancer. Cancer
Res. 59:3570–3575. 1999.PubMed/NCBI
|
|
29
|
Debniak T, Kurzawski G, Gorski B, Kladny
J, Domagala W and Lubinski J: Value of pedigree/clinical data,
immunohistochemistry and microsatellite instability analyses in
reducing the cost of determining hMLH1 and hMSH2 gene mutations in
patients with colorectal cancer. Eur J Cancer. 36:49–54. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ali AY, Farrand L, Kim JY, Byun S, Suh JY,
Lee HJ and Tsang BK: Molecular determinants of ovarian cancer
chemoresistance: New insights into an old conundrum. Ann N Y Acad
Sci. 1271:58–67. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Thibault B, Castells M, Delord JP and
Couderc B: Ovarian cancer microenvironment: Implications for cancer
dissemination and chemoresistance acquisition. Cancer Metastasis
Rev. 33:17–39. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Li M, Yin J, Mao N and Pan L: Upregulation
of phosphorylated cofilin 1 correlates with taxol resistance in
human ovarian cancer in vitro and in vivo. Oncol Rep. 29:58–66.
2013.PubMed/NCBI
|
|
33
|
Mok SC, Bonome T, Vathipadiekal V, Bell A,
Johnson ME, Wong KK, Park DC, Hao K, Yip DK, Donninger H, et al: A
gene signature predictive for outcome in advanced ovarian cancer
identifies a survival factor: Microfibril-associated glycoprotein
2. Cancer Cell. 16:521–532. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Fullwood P, Marchini S, Rader JS, Martinez
A, Macartney D, Broggini M, Morelli C, Barbanti-Brodano G, Maher ER
and Latif F: Detailed genetic and physical mapping of tumor
suppressor loci on chromosome 3p in ovarian cancer. Cancer Res.
59:4662–4667. 1999.PubMed/NCBI
|
|
35
|
Chng HW, Camplejohn RS, Stone MG, Hart IR
and Nicholson LJ: A new role for the anti-apoptotic gene A20 in
angiogenesis. Exp Cell Res. 312:2897–2907. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Shridhar V, Staub J, Huntley B, Cliby W,
Jenkins R, Pass HI, Hartmann L and Smith DI: A novel region of
deletion on chromosome 6q23.3 spanning less than 500 Kb in high
grade invasive epithelial ovarian cancer. Oncogene. 18:3913–3918.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Shayesteh L, Lu Y, Kuo WL, Baldocchi R,
Godfrey T, Collins C, Pinkel D, Powell B, Mills GB and Gray JW:
PIK3CA is implicated as an oncogene in ovarian cancer. Nat Genet.
21:99–102. 1999. View
Article : Google Scholar : PubMed/NCBI
|
|
38
|
Cheaib B, Auguste A and Leary A: The
PI3K/Akt/mTOR pathway in ovarian cancer: Therapeutic opportunities
and challenges. Chin J Cancer. 34:4–16. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Friedlander ML, Russell K, Millis S,
Gatalica Z, Bender R and Voss A: Molecular profiling of clear cell
ovarian cancers: Identifying potential treatment targets for
clinical trials. Int J Gynecol Cancer. 26:648–654. 2016. View Article : Google Scholar : PubMed/NCBI
|
